Welcome to our dedicated page for Livanova Plc SEC filings (Ticker: LIVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LivaNova PLC filings document the regulatory disclosures of an England and Wales public limited company with ordinary shares listed on Nasdaq under LIVN. Its Form 8-K reports primarily cover operating and financial results, earnings releases, business update calls, material events, and governance changes involving senior officers.
Proxy materials describe annual general meeting procedures, shareholder voting matters, director and governance proposals, and the company’s ordinary share structure. The filings also provide formal records for capital-structure disclosures and corporate governance matters relevant to LivaNova’s medical technology operations in neurological and cardiac conditions.
LivaNova PLC director Peter M. Wilver reported routine equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were settled into ordinary shares under the company’s 2025 Director Incentive Award Plan, and 486 ordinary shares were withheld to satisfy tax liabilities at a reference price of $79.70 per share. Following these transactions, he held 10,294 ordinary shares directly. On the same date, he received a new grant of 2,383 RSUs that each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan terms. No open-market purchases or sales were reported.
LivaNova PLC director Todd C. Schermerhorn reported compensation-related equity activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs were exercised into ordinary shares, and 486 shares were withheld at $79.70 per share to satisfy tax liabilities, leaving him with 12,619 ordinary shares directly owned.
On the same date, he received a new grant of 2,383 RSUs under LivaNova’s 2025 Director Incentive Award Plan, each representing a right to one ordinary share. These RSUs vest on June 15, 2027, subject to continued service and the plan’s terms. The tax withholding is an administrative disposition, not an open-market sale.
LivaNova PLC director Francesco Bianchi reported several equity transactions involving company ordinary shares and restricted stock units. He sold 1,200 ordinary shares in an open-market transaction at $80.19 per share and held 9,584 shares directly after the transactions. On the same date, vested restricted stock units were exercised, delivering 4,042 ordinary shares, with 486 shares withheld to satisfy tax liabilities at a price of $79.70 per share. Bianchi also received a new grant of 2,383 restricted stock units that each represent a right to receive one ordinary share, scheduled to vest on June 15, 2027 subject to continued service.
LivaNova PLC director Susan M. Podlogar reported compensation-related share activity tied to restricted stock units (RSUs). On June 15, 2026, vested RSUs were settled into 4,042 ordinary shares, and 486 shares were withheld at $79.70 per share to satisfy tax liabilities. Following these transactions, she directly owned 5,642 ordinary shares of LivaNova PLC.
On the same date, Podlogar also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan. Each RSU represents one ordinary share, scheduled to vest on June 15, 2027, subject to continued service and the plan’s award agreement.
LivaNova PLC director Barry James Christopher reported equity compensation activity involving restricted stock units (RSUs) and ordinary shares. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares. Of these, 486 shares were withheld to cover tax liabilities, leaving him with 7,918 ordinary shares held directly after the tax-withholding disposition and 8,404 ordinary shares following all transactions. He also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.
LivaNova PLC Chief Innovation Officer Ahmet Tezel reported routine equity compensation activity. On June 15, 2026, 2,965 restricted stock units vested and were settled in ordinary shares under the company’s incentive plan. To cover tax liability, 1,032 of these shares were withheld, a non-market disposition.
After these transactions, Tezel directly holds 6,090 ordinary shares and 5,931 unvested restricted stock units that remain subject to future vesting and forfeiture conditions. The filing reflects compensation-related equity vesting rather than open-market buying or selling.
Nygaard-Andersen Jette reported acquisition or exercise transactions in this Form 4 filing.
LivaNova PLC director Jette Nygaard-Andersen received a grant of 2,383 Restricted Stock Units (RSUs) as equity compensation. Each RSU represents a contingent right to receive one ordinary share of the company under the 2025 Director Incentive Award Plan and its award agreement.
The RSUs vest on June 15, 2027, subject to continued service through the vesting period and compliance with the plan terms. Following this grant, Nygaard-Andersen holds 2,383 RSUs directly, all tied to future delivery of ordinary shares if vesting conditions are met.
LivaNova PLC director William A. Kozy reported equity compensation-related transactions involving ordinary shares and restricted stock units. On June 15, 2026, previously vested RSUs were settled into 5,681 ordinary shares, and 682 of those shares were withheld to satisfy tax liability, leaving him with 37,566 ordinary shares held directly.
Kozy also received a new grant of 2,383 restricted stock units under the company’s 2025 Director Incentive Award Plan. These RSUs each represent a right to receive one ordinary share and are scheduled to vest on June 15, 2027, subject to continued service and the plan’s terms.
LivaNova PLC director Stacy Enxing Seng reported routine equity compensation activity. On June 15, 2026, vested restricted stock units were settled into 4,042 ordinary shares, classified as an option/RSU exercise. To cover related taxes, 486 ordinary shares were withheld at $79.70 per share rather than sold on the open market.
Following these transactions, she directly holds 15,307 ordinary shares. Enxing Seng also received a new grant of 2,383 restricted stock units under LivaNova’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service and plan terms.
LivaNova PLC director Story Brooke reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On June 15, 2026, 4,042 RSUs vested and were exercised into ordinary shares, and 486 of those shares were withheld to satisfy tax liabilities at a price of $79.70 per share.
Following these transactions, Brooke directly holds 9,788 ordinary shares. On the same date, Brooke also received a new grant of 2,383 RSUs under the company’s 2025 Director Incentive Award Plan, which are scheduled to vest on June 15, 2027, subject to continued service.